Unraveling Regulatory Programs for NF-kappaB, p53 and MicroRNAs in Head and Neck Squamous Cell Carcinoma

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yan, Bin ^a   Li, Huai ^b   Yang, Xinping ^c   Shao, Jiaofang ^a   Jang, Minyoung ^c,d   Guan, Daogang ^a   Zou, Sige ^b   Van Waes, Carter ^c   Chen, Zhong ^c   Zhan, Ming ^e  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d PFIZER INC   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 21; MICRORNA 34AC; PROTEIN P53; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CARCINOMA CELL; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENE SILENCING; GENE TARGETING; GROWTH REGULATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR MODEL; PREDICTION; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; REGULATORY MECHANISM; VALIDATION STUDY;

CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS; NF-KAPPA B; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884394298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073656     Document Type: Article

References (69)

1. Chen G, Jensen ST, Stoeckert CJ Jr, (2007) Clustering of genes into regulons using integrated modeling-COGRIM. Genome Biol 8: R4.
2. Tang B, Hsu HK, Hsu PY, Bonneville R, Chen SS, et al. (2012) Hierarchical modularity in ERalpha transcriptional network is associated with distinct functions and implicates clinical outcomes. Sci Rep 2: 875.
3. Li H, Sun Y, Zhan M, (2007) The discovery of transcriptional modules by a two-stage matrix decomposition approach. Bioinformatics 23: 473-479.
4. Geeven G, van Kesteren R, Smit A, de Gunst M, (2012) Identification of context-specific gene regulatory networks with GEMULA - gene expression modeling using LAsso. Bioinformatics 28: 214-221.
5. Georgiev P, Theis F, Cichocki A, Bakardjian H (2006) Sparse component analysis: a new tool for data mining. Biocomputing: Kluwer Academic Publishers.
6. Dueck D, Morris QD, Frey BJ, (2005) Multi-way clustering of microarray data using probabilistic sparse matrix factorization. Bioinformatics 21Suppl 1: i144-i151.
7. Pournara I, Wernisch L (2008) Using temporal correlation in factor analysis for reconstructing transcription factor activities. EURASIP J Bioinform Syst Biol: 172840.
8. Liao JC, Boscolo R, Yang YL, Tran LM, Sabatti C, et al. (2003) Network component analysis: reconstruction of regulatory signals in biological systems. Proc Natl Acad Sci U S A 100: 15522-15527.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
10. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB, (2011) NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30: 1615-1630.
11. Schneider G, Kramer OH, (2011) NFkappaB/p53 crosstalk-a promising new therapeutic target. Biochim Biophys Acta 1815: 90-103.
12. Hayden MS, Ghosh S, (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-362.
13. Menendez D, Inga A, Resnick MA, (2009) The expanding universe of p53 targets. Nat Rev Cancer 9: 724-737.
14. Sidransky D, (2002) Emerging molecular markers of cancer. Nat Rev Cancer 2: 210-219.
15. Yan B, Yang X, Lee TL, Friedman J, Tang J, et al. (2007) Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-kappaB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 8: R78.
16. Yan B, Chen G, Saigal K, Yang X, Jensen ST, et al. (2008) Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status. Genome Biol 9: R53.
17. Karin M, (2006) NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45: 355-361.
18. Baud V, Karin M, (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
19. Chen Z, Yan B, Van Waes C, (2008) The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas. Biomark Med 2: 409-426.
20. Lu H, Yang X, Duggal P, Allen CT, Yan B, et al. (2011) TNF-alpha promotes c-REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 71: 6867-6877.
21. Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, et al. (2010) CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules. Clin Cancer Res 16: 2295-2307.
22. Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, et al. (1999) Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 26: 119-129.
23. Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, et al. (2005) Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 65: 7071-7080.
24. Noda C, Murata T, Kanda T, Yoshiyama H, Sugimoto A, et al. (2011) Identification and characterization of CCAAT enhancer-binding protein (C/EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent membrane protein 1. J Biol Chem 286: 42524-42533.
25. Shin JA, Kim JJ, Choi ES, Shim JH, Ryu MH, et al. (2012) In vitro apoptotic effects of methanol extracts of Dianthus chinensis and Acalypha australis L. targeting specificity protein 1 in human oral cancer cells. Head Neck.
26. Lee TL, Yeh J, Friedman J, Yan B, Yang X, et al. (2008) A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122: 1987-1998.
27. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, et al. (2004) Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23: 6105-6114.
28. Pensa S, Watson CJ, Poli V, (2009) Stat3 and the inflammation/acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia 14: 121-129.
29. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, et al. (2002) Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 277: 25032-25039.
30. Takahra T, Smart DE, Oakley F, Mann DA, (2004) Induction of myofibroblast MMP-9 transcription in three-dimensional collagen I gel cultures: regulation by NF-kappaB, AP-1 and Sp1. Int J Biochem Cell Biol 36: 353-363.
31. Papagiannakopoulos T, Shapiro A, Kosik KS, (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68: 8164-8172.
32. Boldin MP, Baltimore D, (2012) MicroRNAs, new effectors and regulators of NF-kappaB. Immunol Rev 246: 205-220.
33. Hermeking H (2009) The miR-34 family in cancer and apoptosis. Cell Death Differ.
34. Lee TL, Yang XP, Yan B, Friedman J, Duggal P, et al. (2007) A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 13: 5680-5691.
35. Hoyer PO, (2004) Non-negative matrix factorization with sparseness constraints. J Mach Learn Res 5: 1457-1469.
36. Yang X, Lu H, Yan B, Romano RA, Bian Y, et al. (2011) DeltaNp63 versatilely regulates a Broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res 71: 3688-3700.
37. Xiao F, Zuo Z, Cai G, Kang S, Gao X, et al. (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37: D105-110.
38. Nguyen DX, Bos PD, Massague J, (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
39. Chen ZG, (2007) Exploration of metastasis-related proteins as biomarkers and therapeutic targets in the treatment of head and neck cancer. Curr Cancer Drug Targets 7: 613-622.
40. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, et al. (2004) Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23: 2484-2498.
41. O'Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, et al. (2005) Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24: 1244-1251.
42. Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, et al. (2007) Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer. Clin Cancer Res 13: 6568-6578.
43. Ikeda A, Sun X, Li Y, Zhang Y, Eckner R, et al. (2000) p300/CBP-dependent and-independent transcriptional interference between NF-kappaB RelA and p53. Biochem Biophys Res Commun 272: 375-379.
44. Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, et al. (2011) ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. OMICS 15: 305-312.
45. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
46. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, et al. (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207-219.
47. Botcheva K, McCorkle SR, McCombie WR, Dunn JJ, Anderson CW, (2011) Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle 10: 4237-4249.
48. Wang J, Ouyang W, Li J, Wei L, Ma Q, et al. (2005) Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. Cancer Res 65: 6601-6611.
49. Wang T, Zou J, Cunningham C, Secombes CJ, (2002) Cloning and functional characterisation of the interleukin-1 beta 1 promoter of rainbow trout (Oncorhynchus mykiss). Biochim Biophys Acta 1575: 108-116.
50. Catron KM, Brickwood JR, Shang C, Li Y, Shannon MF, et al. (1998) Cooperative binding and synergistic activation by RelA and C/EBPbeta on the intercellular adhesion molecule-1 promoter. Cell Growth Differ 9: 949-959.
51. Tamura M, Sebastian S, Yang S, Gurates B, Fang Z, et al. (2002) Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2. J Clin Endocrinol Metab 87: 3263-3273.
52. Li X, Liao WS, (1992) Cooperative effects of C/EBP-like and NF kappa B-like binding sites on rat serum amyloid A1 gene expression in liver cells. Nucleic Acids Res 20: 4765-4772.
53. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97: 4227-4232.
54. Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, et al. (2000) Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? Faseb J 14: 1499-1507.
55. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, et al. (1999) Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59: 3468-3474.
56. Rasmussen MK, Iversen L, Johansen C, Finnemann J, Olsen LS, et al. (2008) IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response. Inflamm Res 57: 329-339.
57. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, et al. (2001) Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61: 5911-5918.
58. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, et al. (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548.
59. Lu SL, Herrington H, Reh D, Weber S, Bornstein S, et al. (2006) Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 20: 1331-1342.
60. Furey TS, (2012) ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nat Rev Genet 13: 840-852.
61. Wu J, Bergholz J, Lu J, Sonenshein GE, Xiao ZX, (2010) TAp63 is a transcriptional target of NF-kappaB. J Cell Biochem 109: 702-710.
62. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, et al. (2007) TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6: 274-285.
63. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA, (2009) MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302.
64. Nohata N, Hanazawa T, Kinoshita T, Okamoto Y, Seki N, (2013) MicroRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma. Auris Nasus Larynx 40: 143-149.
65. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359.
66. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, et al. (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128-2136.
67. Bader AG, (2012) miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 3: 120.
68. Yang S, Li Y, Gao J, Zhang T, Li S, et al. (2012) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene.
69. Yamazaki H, Chijiwa T, Inoue Y, Abe Y, Suemizu H, et al. (2012) Overexpression of the miR-34 family suppresses invasive growth of malignant melanoma with the wild-type p53 gene. Exp Ther Med 3: 793-796.